ROWAN, a digital therapeutics company, said on the 22nd that it signed a domestic supply and exclusive sales agreement with Hyundai Pharm for the cognitive intervention therapy solution "SuperBrain H."
Under the agreement, the two sides plan to push to expand the cognitive intervention therapy market. Hyundai Pharm, in particular, will use its sales network in neurology and psychiatry to increase distribution mainly to small and midsize hospitals with fewer than 300 beds and clinic-level medical institutions. The plan aims to improve access so patients can receive cognitive management at local primary care facilities rather than only at large hospitals.
"SuperBrain H" is a digital solution designed to help clinicians efficiently run cognitive intervention therapy in clinical settings for patients with mild cognitive impairment. As the holder of the core technology, ROWAN will provide content, manage the system, and offer technical support, taking responsibility for product quality.
ROWAN plans to grow this collaboration beyond simple distribution into a business model in which Digital Healthcare corporations and pharmaceutical companies work together. To that end, ROWAN will continue product training and technical support for Hyundai Pharm's dedicated team, and Hyundai Pharm will use its sales capabilities to drive market expansion. ROWAN plans to strengthen SuperBrain's position in Korea's cognitive intervention therapy market through this effort.
Han Seung-hyeon, CEO of ROWAN, said, "This partnership will serve as an opportunity to broaden practical treatment alternatives in clinical settings," and added, "We will also push step by step into overseas markets going forward."